← Back to Search

Other

NNC0247-0829 for Obesity

Phase 1
Waitlist Available
Research Sponsored by Novo Nordisk A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from day 1 (pre-dose) until completion of the post-treatment follow-up visit (from day 71 up to day 134, depending on the dose cohort)

Summary

This trial tests a new medicine called NNC0247-0829 to help people with overweight or obesity manage their weight. Participants will receive injections of either the medicine or a non-active substance. Researchers will monitor their health and weight through various tests.

Eligible Conditions
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 1 (pre-dose) until completion of the post-treatment follow-up visit (from day 71 up to day 134, depending on the dose cohort)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 1 (pre-dose) until completion of the post-treatment follow-up visit (from day 71 up to day 134, depending on the dose cohort) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
For multiple dose (MD) cohorts: Number of treatment emergent adverse events (TEAEs)
For single dose (SD) cohorts: Number of treatment emergent adverse events (TEAEs)
Secondary study objectives
For (SD) cohorts: The area under the NNC0247-0829 serum concentration-time curve from time 0 to infinity
For MD cohorts: Number of injection site reactions
For MD cohorts: Occurrence of anti-NNC0247-0829 antibodies
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active treatment NNC0247-0829Experimental Treatment1 Intervention
Up to 6 single dose cohorts are planned with 10 subjects in each; 8 will receive active treatment. Up to 2 multiple dose cohorts are planned with 12 subjects in each; 8 will receive active treatment
Group II: PlaceboPlacebo Group1 Intervention
In each of the 6 single dose cohorts, 2 subjects will receive placebo. In the 2 multiple dose cohorts, 4 subjects will receive placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NNC0247-0829
2019
Completed Phase 1
~110

Find a Location

Who is running the clinical trial?

Novo Nordisk A/SLead Sponsor
1,549 Previous Clinical Trials
2,443,929 Total Patients Enrolled
152 Trials studying Obesity
143,392 Patients Enrolled for Obesity
Clinical Reporting Anchor and Disclosure (1452)Study DirectorNovo Nordisk A/S
104 Previous Clinical Trials
103,155 Total Patients Enrolled
28 Trials studying Obesity
43,530 Patients Enrolled for Obesity
~16 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top